Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Foundation Medicine Inc    FMI

FOUNDATION MEDICINE INC (FMI)
My previous session
Most popular
  Report  
SummaryQuotesNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Foundation Medicine : Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Foundation Medicine, Inc. FMI

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 07:35pm CEST

By a News Reporter-Staff News Editor at Managed Care Weekly Digest -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the September 26, 2017 deadline in the class action lawsuit filed on behalf of investors who purchased Foundation Medicine, Inc. ("Foundation" or the "Company") (NASDAQ: FMI) securities between February 26, 2014 and November 3, 2015, inclusive (the "Class Period"). Foundation investors have until September 26, 2017 to file a lead plaintiff motion. To obtain information or participate in the class action, please visit the Foundation case page on our website at www.glancylaw.com/case/foundation-medicine-inc (see also Glancy Prongay and Murray LLP).

The Complaint filed in this class action alleges that, during the Class Period, the Company made false and misleading statements and/or failed to disclose adverse information regarding the Company's business and prospects. Specifically, the complaint alleges that the defendants made false and/or misleading statements regarding: (i) the reimbursement process and likelihood of coverage for Foundation's tumor tests by Medicare; and (ii) the Company's financial guidance. As a result of these false statements, Foundation common stock traded at artificially inflated prices during the Class Period.

On July 29, 2015, the Company disclosed that "clinical volume growth was affected by slower than anticipated progress towards obtaining a local coverage determination from our regional Medicare Administrative Contractor (MAC) and by some competitive noise in the market" and that, as such, the Company was "adjusting" its guidance for clinical volume and annual revenues. Then, on November 3, 2015, the Company disclosed a further revision to the already reduced number of clinical tests it expected to report for 2015.

On this news, the price of Foundation common stock fell $6.62 per share, to close at $17.31 per share on November 4, 2015.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased shares of Foundation during the Class Period you may move the Court no later than September 26, 2017 to ask the Court to appoint you as lead. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. View source version on businesswire.com: http://www.businesswire.com/news/home/20170925006403/en/

Keywords for this news article include: Medicare, Legal Issues, Health Policy, Glancy Prongay and Murray LLP.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

Stocks mentioned in the article
ChangeLast1st jan.
FOUNDATION MEDICINE INC 0.00%-End-of-day quote.0.00%
ROCHE HOLDING LTD. -0.19% 238.15 Delayed Quote.-3.39%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on FOUNDATION MEDICINE INC
08/10FOUNDATION MEDICINE : UC Davis - Liquid biopsy could ease the way to immunothera..
AQ
08/09FOUNDATION MEDICINE : Management's Discussion and Analysis of Financial Conditio..
AQ
08/09FOUNDATION MEDICINE : Genetic Mutations of Appendix Cancer Identified, May Impac..
AQ
08/08FOUNDATION MEDICINE : Blood-based assay could predict Tecentriq's benefit in NSC..
AQ
08/07FOUNDATION MEDICINE : Roche Purchases Shares in Tender Offer for FMI
AQ
08/07FOUNDATION MEDICINE : Setting the Pace for Blood Tumor Mutational Burden
PU
08/06FOUNDATION MEDICINE : Publishes New Data in Nature Medicine Supporting Blood Tum..
BU
07/31FOUNDATION MEDICINE, INC. : Termination of a Material Definitive Agreement, Comp..
AQ
07/31ROCHE : Purchases Shares in Tender Offer for FMI
AQ
07/28ROCHE : and Foundation Medicine Reach Merger Agreement
AQ
More news
News from SeekingAlpha
08/08YOUR DAILY PHARMA SCOOP : Foundation Promising, Paratek Moves Up, Ovid Down 
08/06Foundation Medicine test helps predict response to Roche's Tecentriq in lung .. 
06/19Midday Gainers / Losers (06/19/2018) 
06/19HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (06/19/2018) 
06/19PREMARKET GAINERS AS OF 9 : 05 am (06/19/2018) 
Financials ($)
Income Statement Evolution
Consensus
 
Mean consensus
Number of Analysts
Average target price -
Spread / Average Target
EPS Revisions
Managers
NameTitle
Troy Cox President & Chief Executive Officer
Konstantin Fiedler Chief Operating Officer
Jason Ryan Chief Financial Officer
Vincent A. Miller Chief Medical Officer
Philip J. Stephens Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
FOUNDATION MEDICINE INC0.00%0
CELLTRION, INC.--.--%30 664
IQVIA HOLDINGS INC23.75%24 655
LONZA GROUP21.15%23 818
INCYTE CORPORATION-31.96%13 686
SEATTLE GENETICS, INC.37.94%11 443